{
    "2020-11-04": [
        [
            {
                "time": "2020-11-04",
                "original_text": "与拜恩泰科合作生变？复星医药：在推动两款新冠疫苗国内上市",
                "features": {
                    "keywords": [
                        "拜恩泰科",
                        "复星医药",
                        "新冠疫苗",
                        "国内上市"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-11-04",
                "original_text": "复星：新冠疫苗临床Ⅰ期进入数据分析阶段，临床Ⅱ期桥接试验积极筹备中",
                "features": {
                    "keywords": [
                        "复星",
                        "新冠疫苗",
                        "临床Ⅰ期",
                        "数据分析",
                        "临床Ⅱ期",
                        "桥接试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-04",
                "original_text": "市场消息：复星医药计划不再继续进行与BioNTech SE合作的、目前已在中国开展测试的新冠疫苗临床测试，转而寻求该公司其他候选新冠疫苗在中国的许可",
                "features": {
                    "keywords": [
                        "复星医药",
                        "BioNTech SE",
                        "新冠疫苗",
                        "临床测试",
                        "候选疫苗",
                        "中国市场"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-11-04",
                "original_text": "复星医药：与BioNTech SE合作的临床Ⅱ期桥接试验积极筹备中",
                "features": {
                    "keywords": [
                        "复星医药",
                        "BioNTech SE",
                        "临床Ⅱ期",
                        "桥接试验"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-04",
                "original_text": "复星医药(02196.HK)拟为控股子公司复星医药产业不超1亿元融资提供担保",
                "features": {
                    "keywords": [
                        "复星医药",
                        "控股子公司",
                        "融资",
                        "担保"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-04",
                "original_text": "A股收盘综述：上证指数缩量小涨，中国人寿、君正集团领跌蚂蚁金服概念股",
                "features": {
                    "keywords": [
                        "A股",
                        "上证指数",
                        "中国人寿",
                        "君正集团",
                        "蚂蚁金服"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-11-04",
                "original_text": "赣锋锂业、复星医药等港股获南向资金持股比例超20%",
                "features": {
                    "keywords": [
                        "赣锋锂业",
                        "复星医药",
                        "港股",
                        "南向资金",
                        "持股比例"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "新能源"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}